6 results about "Docosahexenoic Acids" patented technology

The invention belongs to the technical field of skin care products, and discloses a quick-acting red-removing repair product which comprises the following components: water, caprylic / capric triglyceride, glycerol, sorbitol, phosphatidylcholine, 1, 3-propylene glycol, xanthan gum, eicosapentaenoic acid, docosahexaenoic acid, phytosphingosine, centella asiatica extract and tocopheryl acetate. A turmeric rhizome extract and 1, 2-hexanediol. Through mutual cooperation of the turmeric root extract and the centella asiatica extract, by taking enhancement of skin immune regulation and skin barrier functions as an action mechanism, on one hand, skin inflammatory response can be inhibited, and inflammation, microorganisms and bacteria can be effectively resisted, and on the other hand, skin barrier reconstruction can be promoted, wound healing can be promoted, and an ECM matrix can be protected; in addition, the eicosapentaenoic acid, the docosahexaenoic acid, the turmeric root extract, the phytosphingosine and the centella asiatica extract are wrapped by the nano-microcapsule liposome, so that the activity of the product can be ensured.

The invention relates to the technical field of gene engineering, and discloses a high-strength promoter, a schizochytrium limacinum engineering bacterium based on the promoter and application of the schizochytrium limacinum engineering bacterium. Phosphoric acid pantetheinyl transferase (PPTase) is a key rate-limiting enzyme for biosynthesis of docosahexaenoic acid. Four high-strength promoters which can be strongly expressed in a schizochytrium limacinum chassis are obtained through screening and comprise a P3431 promoter, a P5659 promoter, a P6631 promoter and a P4862 promoter, and the nucleotide sequences of the promoter are shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 respectively; furthermore, the high-strength promoter is connected with PPTase and is integrated into a schizochytrium limacinum genome, so that the yield of the docosahexaenoic acid is remarkably increased. After a P3431 promoter, a P5659 promoter, a P6631 promoter and a P4862 promoter are respectively connected with PPTase and are transferred into schizochytrium limacinum for expression, the docosahexaenoic acid yield is respectively increased by 25%, 37.5%, 43% and 36.5% compared with that of a wild type.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The invention provides a method for blocking endothelial cell apoptosis induced by docosahexaenoic acid (DHA) through a p38MAPK inhibitor, and relates to the technical field of biology. According to the method, endothelial cells serve as a research model, and cell apoptosis induced by high-concentration docosahexaenoic acid (DHA) is remarkably reduced by adding a p38MAPK specific inhibitor. The method comprises the following specific steps: cell culture, DHA and inhibitor treatment, and detection of the apoptosis rate by using flow cytometry. Experimental results show that the p38MAPK inhibitor can effectively reduce cell apoptosis caused by DHA (docosahexaenoic acid). The method has the advantages that the method is simple and efficient, the effect of the p38MAPK signal channel in DHA-induced endothelial cell apoptosis is further disclosed, and a theoretical basis and a practical basis are provided for developing novel medicines for treating endothelial dysfunction related diseases.

Disclosed are methods for assessing the presence or absence of a therapeutic concentration of a deuterated docosahexaenoic acid during treatment of a patient with a retinal or neuronal oxidative disease.

This invention discloses a *Acer truncatum* seed oil-PS composite composition that promotes nerve development, belonging to the field of food nutrition technology. The composite composition comprises the following components by weight: 8-12 parts *Acer truncatum* seed oil, 3-6 parts phosphatidylserine, 1-2 parts phospholipids, 2-4 parts flaxseed oil, 0.5-2 parts arachidonic acid phosphatidylinositol, 1-3 parts docosahexaenoic acid phospholipids, 0.3-1.5 parts sialic acid, 0.2-1 parts phytosterols, 0.1-0.8 parts d-α-tocopherol, 0.5-2 parts emulsifier, and 0.05-0.3 parts antioxidant synergist. This invention scientifically combines multiple nutritional components to form a synergistic system, meeting the nutritional needs of nerve development, providing comprehensive nutritional support, and significantly enhancing the promotion effect. Simultaneously, it constructs a brain-targeting lipid-phospholipid hybrid nanocarrier, combined with refined processing, to improve the targeting and bioavailability of the composition, retaining biological activity, and possessing good storage properties and safety for use, facilitating widespread application.